http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#Head
http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#assertion
http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#provenance
http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#pubinfo
http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#assertion
http://purl.obolibrary.org/obo/DOID_3908
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_3908
http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00441
http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#association
http://www.w3.org/2000/01/rdf-schema#label
gemcitabine for injection is a nucleoside metabolic inhibitor indicated in combination with carboplatin for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum based therapy 1 1 in combination with paclitaxel for first line treatment of metastatic breast cancer after failure of prior anthracycline containing adjuvant chemotherapy unless anthracyclines were clinically contraindicated 1 2 in combination with cisplatin for the treatment of non small cell lung cancer 1 3 as a single agent for the treatment of pancreatic cancer 1 4 gemcitabine for injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum based therapy gemcitabine for injection in combination with paclitaxel is indicated for the first line treatment of patients with metastatic breast cancer after failure of prior anthracycline containing adjuvant chemotherapy unless anthracyclines were clinically contraindicated gemcitabine for injection is indicated in combination with cisplatin for the first line treatment of patients with inoperable locally advanced stage iiia or iiib or metastatic stage iv non small cell lung cancer gemcitabine for injection is indicated as first line treatment for patients with locally advanced nonresectable stage ii or stage iii or metastatic stage iv adenocarcinoma of the pancreas gemcitabine for injection is indicated for patients previously treated with 5 fu
http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB00441
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#provenance
http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#pubinfo
http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#sig
http://purl.org/nanopub/x/hasSignature
LpEG6isIg/dD5Ab1zD+u5vKd9auQnpW1umKYR3A6qXr7XDnXCLX2JTpWtWJTH8QxqRCCmH9iMAUqWKzyQ92grBg1rzxecGCTKOYo4EV62kDajoXVXsfC7DFcAl6MM9aL5eb6pEWKbzmYa53l4lwTU54XxPUIq2VfPkWqgj000vY=
http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM
http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM
http://purl.org/dc/terms/created
2021-06-15T17:51:32.201+02:00
http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RA_xAnack6nkwBuOlJ5XUeZQM9bxJMSZGtci6RbxGxveM
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs